NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Nordion Inc. (NYSE: NDZ), Abbott Laboratories (NYSE: ABT), Covidien plc (NYSE: COV), DaVita HealthCare Partners Inc. (NYSE: DVA), and Sirona Dental Systems Inc. (NASDAQ: SIRO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Nordion Inc. Analyst Notes
On March 28, 2014, Nordion Inc. (Nordion) announced that it has entered into a definitive agreement to be acquired by Sterigenics, in a transaction valued at approximately $727 million. The Company informed that pursuant to the terms of this agreement, shareholders will receive an aggregate cash consideration of $11.75 per share. Additionally, the Company stated that upon closing of this transaction, Nordion will operate as a standalone company within Sterigenics and will continue to operate with its own name. The Company informed that the transaction will be funded using a combination of new debt facilities and equity financing, both of which are fully committed, Sterigenics' cash on hand, and a portion of Nordion's cash on hand. Commenting on the acquisition, Steve West, CEO of Nordion, stated, "This transaction delivers value to our shareholders and is a good strategic fit for Nordion. We believe this partnership is beneficial to Nordion's employees and our customers, as Nordion and Sterigenics combine their global expertise, industry knowledge and the same focus on high quality standards and values. This transaction also marks the successful completion of Nordion's strategic review." The full analyst notes on Nordion Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/NDZ/report.pdf
--
Abbott Laboratories Analyst Notes
On March 28, 2014, Abbott Laboratories (Abbott) announced that the U.S. Food and Drug Administration (FDA) has approved its Supera® Peripheral Stent System to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). According to the Company, PAD occurs when fat and cholesterol buildup causes arteries outside of the heart to narrow, which reduces blood flow to parts of the body, most commonly the legs. Commenting on the approval, Chuck Foltz, Senior Vice President, Vascular, Abbott, said "FDA approval of the Supera stent provides an additional treatment option that can make a positive impact on the lives of people suffering from peripheral artery disease. FDA approval of the Supera stent gives Abbott rapid entry into one of the fastest-growing segments of the peripheral stent market, providing Abbott with one of the most comprehensive and competitive peripheral technology portfolios in the industry." The full analyst notes on Abbott Laboratories are available to download free of charge at:
http://www.AnalystsReview.com/04112014/ABT/report.pdf
--
Covidien plc Analyst Notes
On March 28, 2014, Covidien plc (Covidien) announced that it has partnered with the AORN Foundation on an initiative that will provide nurse leaders with a core set of financial and management tools to complement their clinical expertise. According to the Company, the new AORN Emerging Leaders educational initiative will comprise five day-long seminars focusing on leadership development and financial concepts necessary for managing the overall performance of perioperative services. Matt Gattuso, President of health systems at Covidien and an AORN Foundation Board Member, stated, "Nurses are on the frontlines of care, and increasingly find themselves at the intersection of improving patient outcomes in a lower cost environment. Covidien is committed to increasing access to quality health care for all, and we believe that improving the financial and managerial skills and abilities of nurse leaders will be a win-win for patient care." The full analyst notes on Covidien plc are available to download free of charge at:
http://www.AnalystsReview.com/04112014/COV/report.pdf
--
DaVita HealthCare Partners Inc. Analyst Notes
On March 18, 2014, DaVita HealthCare Partners Inc. (DaVita) announced that Javier Rodriguez has transitioned from President to CEO of DaVita's Kidney Care Division. According to the Company, Kent Thiry will remain CEO of DaVita as well as Co-Chairman of the Board of Directors. Commenting on this transition, Thiry stated, "Javier is a dynamic, decisive leader who has played a key role in DaVita's success. He's been with me since my first day as CEO nearly 15 years ago and I couldn't be happier or prouder to see him take over leadership of our kidney care business." The full analyst notes on DaVita HealthCare Partners Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/DVA/report.pdf
--
Sirona Dental Systems Inc. Analyst Notes
On March 24, 2014, Sirona Dental Systems Inc. (Sirona) reported that it has once again received the renowned iF product design award. According to the Company, Johannes Krug, Product Manager Lab hardware at Sirona, accepted the coveted award at BMW Welt in Munich. Commenting on the recognition, Krug stated, "Good design is not an end in itself; rather it makes an essential contribution to the fact that our products are easier to handle. The user-friendliness and quality of our products is confirmed again and again with every design award." The full analyst notes on Sirona Dental Systems Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/SIRO/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
